LYMRIT 37‐01: UPDATED RESULTS OF A PHASE I/II STUDY OF 177LU‐LILOTOMAB SATETRAXETAN, A NOVEL CD37‐TARGETED ANTIBODY‐ RADIONUCLIDE‐CONJUGATE IN RELAPSED NHL PATIENTS. (June 2017) - Kolstad, A.; Madsbu, U.; Beasley, M.; Bayne, M.; Illidge, T.; O'Rourke, N.; Lagerlöf, I.; Hájek, R.; Jurczak, W.; Willenbacher, E.; Blakkisrud, J.; Muftuler Løndalen, A.; et al.